SineuGene Therapeutics is a biopharmaceutical company focusing on gene therapy for brain disorders. Founded in late 2021, the company builds on more than a decade of research on neuroscience by JiaLab at Tsinghua University's School of Medicine.

SineuGene has established innovative animal disease models, such as fruit flies, mice, and Bama pigs, to better understand the characteristics of neurological diseases and identify viable targets for drug development. The company has also developed a platforam for screening central nervous system-specific adeno-associated viruses (AAVs) with high targeting specificity, delivery efficiency, and low immunogenicity. We have also established a platform for developing central nervous system small nucleic acid drugs, covering target screening, sequence design optimization, nucleic acid synthesis, chemical modifications, and delivery technology development. With its expertise in gene expression and editing technology, and nucleic acid-mediated gene expression regulation, SineuGene is committed to developing effective treatments for neurological diseases such as ALS, stroke, Parkinson's disease, Alzheimer's disease, Huntington's chorea, and Autism spectrum disorder.

SineuGene's three co-founders, Professor Jia Yichang (Founder), Dr. Peng Lin (CEO), and Dr. Guo Wei (CSO), all have backgrounds in Tsinghua University, forming a complementary triangle between academia, industry, and research. Over 70% of team members have master's or doctoral degrees from renowned domestic and foreign institutions, such as Tsinghua University, Peking University, the Chinese Academy of Sciences, the Beijing Institute of Life Sciences, and Leibniz University Hannover (Germany), with extensive experience in drug development, clinical operations, and basic research. To support drug development through the entire process, the company has built a modular platform covering target discovery, conceptual verification, screening and optimization, preclinical studies, CMC, regulatory submission, and medical and clinical operations.

SineuGene's vision is to provide effective and safe gene therapy solutions for patients worldwide suffering from neurological diseases.